GIRON, DANIELLE,HAMMERSCHMIDT, WALTER,PIECHON, PHILIPPE,POLASEK, JOHANNE,SCHREINER, ANDREAS,STOWASSER, FRANK
申请号：
NZ60088709
公开号：
NZ600887A
申请日:
2009.03.18
申请国别(地区):
NZ
年份:
2013
代理人:
摘要：
600887 A substantially pure crystalline hemi-pentahydrate form of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salt characterized by the x-ray powder diffraction pattern that shows a characteristic maxima at 22.5 degrees, 2 theta. Also disclosed are pharmaceutical composition comprising the crystalline form and the use of the crystalline form in the manufacture of a medicament. The medicament is useful in the treatment of prostate cancer, colorectal cancer, breast cancer, multiple myeloma, pancreatic cancer, small cell carcinoma, acute myelogenous leukaemia, chronic myelogenous leukaemia, myelo-proliferative disease, non-small cell leukaemia, small cell leukaemia, chronic lymphoid leukaemia, sarcoma, melanoma, lymphoma, thyroid cancer, neuroendocrine cancer, renal cell cancer, gastric cancer, gastrointestinal stromal cancer, glioma, brain cancer, bladder cancer and cholangiocarcinoma.
